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Introduction. To evaluate the eﬃcacy of epoetin-α prior to revision total knee arthroplasty, we hypothesized that epoetin-α will
reduce blood transfusion. Methods. Eighty-one patients were compared in this retrospective review; twenty-eight patients received
our dosing regimen. All patients were mildly anemic. Epoetin-α to control (1 : 2) patient matching occurred so that one of two
attending surgeons, gender, BMI, complexity of surgery, ASA score, and age were similar between groups. The clinical triggers
for blood transfusion during or after the procedure were determined based on peri- and postoperative hemoglobin levels, ASA
score, and/or clinical symptoms consistent with anemia. Blood salvage was not used. Results. Blood transfusion and length of stay
were lower in the study group. None of the patients who received epoetin-α underwent transfusion. Hemoglobin increased from
11.97 to 13.8, preoperatively. Hemoglobin at day of surgery and time of discharge were higher. Gender, BMI, ASA score, total and
hidden blood losses, calculated blood loss, preop PLT, PT, PTT, and INR were similar between groups. One Epogen patient had
an uncomplicated DVT (3.6%). Conclusions. Epoetin-α may have a role in the mildly anemic revision knee patient. It may also
decrease patient length of stay allowing for earlier readiness to resume normal activities and/or meet short-term milestones. A
randomized study to evaluate the direct and indirect costs of such a treatment methodology in the mildly anemic revision patient
may be warranted.
1. Introduction
Revision knee arthroplasty (TKA) is known to cause substan-
tial blood loss. It also increases blood transfusions through-
out the perioperative period [1]. Losses can typically range
from 1 to 1.5 L (∼3.85 ± 1.4 g hgb) [2–4]. Furthermore,
revisions may require as much as 3 to 4 units of transfused
blood [1]. Since substantial blood loss increases the need for
transfusion and may extend length of stay, we are interested
in the eﬀect of preoperative epoetin-α on the revision knee
patient.
Allogeneic transfusion is associated with numerous risks
[1, 5–7]. Preoperative autologous donation can be inconve-
nient, wasteful, and expensive [8]. It can also induce anemia
and therefore should be avoided in the mildly anemic
patient (preoperative hemoglobin (Hb) between 10.0 g/dL
and 13.0 g/dL) [8]. However, recent literature suggests knee
arthroplasty patients may benefit from pre-operative epo-
etin-α injection [9]; it’s use in cancer, chronic renal failure,
critical care, and orthopaedic trauma patients has also shown
promising results [10].
A paucity of information is available on preoperative
epoetin-α use in the revision knee patient. We studied a
consecutive series of mildly anemic patients (10.0–13.0 g/dL)
who underwent a revision knee surgery. We hypothesized
that mildly anemic patients who receive epoetin-α will
receive fewer transfusions. This patient population is thought
to have a fourfold and fifteenfold transfusion rate increase
over those with hemoglobin levels between 13.0–15.0 g/dL
and >15 g/dL, respectively [11, 12].
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Table 1: Demographic data.
Characteristic Epoetin-α Control P-value
Age (y) 63.7 64.4 0.707
BMI (kg/m2) 35.9 32.5 0.125
ASA score (no.) 2.59 2.48 0.663
INR 1.056 1.06 0.427
Platelet count (per mm3) 263,070 237,360 0.761
Sg Duration (min) 85.4 92.7 0.276
Length of Stay (days) 3 3.67 0.042
2. Methods
Following Institutional Review Board (IRB) approval, we
performed this retrospective analysis. Between January 2007
and May 2010 there were 81 patients who met our inclusion
and exclusion criteria (see below); twenty-eight of these
patients electively received epoetin-α. All patients received a
revision knee surgery for prosthesis wear out and/or loosen-
ing. All surgical procedures were elective. The following cases
were excluded from the study: subjects with pre-operative
Hb values less than 10 g/dL or greater than 13 g/dL, patients
with hematological diseases or coagulation disorders, a
history of prior deep venous thrombosis or a pulmonary
embolus, periprosthetic infection, and subjects who received
a postoperative drain. We defined mildly anemic patients
as those with an Hb level at or below 13 g/dL and at or
above 10 g/dL [11, 12]. Any patient, during pre-operative
evaluation, who had an Hb level of <9 g/dL, was referred to a
hematologist for further evaluation.
When a hemoglobin level was ≥10 and ≤13 g/dL, then
epoetin-α was considered 21, 14, and 7 days prior to surgery.
All mildly anemic patients at our site of practice are referred
to an expert who explains the risks and benefits of treatments
for preoperative anemia—all risks associated with epoetin-α
use were discussed. Patients that did and did not receive
epoetin-α who met the study inclusion criteria were patient-
matched (1 : 2) according to one of two attending surgeons,
gender, bmi, complexity of surgery, ASA score, and age. All
patients were oﬀered oral multivitamins, vitamin B12, folic
acid, and iron.
The preoperative workup, surgical technique, anesthesia,
and postoperative management of patients in both groups
were identical. All surgeries were completed under com-
bined spinal-epidural anesthesia, with tourniquet control. A
straight medial parapatellar approach was made to the left
or right knee incorporating the old incision. A synovectomy
occurred in all cases. All knees were cemented. We do not
use a lateral release. Neither cell saver nor drains were used;
at our institution, it is not a routine practice. Through 4-
weeks post-op, proper anticoagulant (either oral warfarin or
subcutaneous enoxaparin) was administered to the patient.
The target INR for all patients was 2.0–2.5. The first dose
of prophylactic antibiotic was administered within one hour
prior to incision and then continued for the first 24 hours.
The clinical triggers for blood transfusion during or after the
procedure were determined based on peri- and postoperative
hemoglobin levels, the ASA score (American Society of
Table 2: Blood data.
Characteristic Epoetin-α Control P-value
Average epoetin-α dose 40,000 u 2.86 0 Na
Epoetin-α eﬀect on Hb (g/dL) 11.97 to 13.8 Na <0.001
Hb at Sg (g/dL) 13.8 12.2 <0.001
Hb on discharge (g/dL) 10.6 9.69 <0.001
Transfusion (%) 0 54 <0.001
Mean TBL (mL) 1670 1737 0.730
Mean HBL (mL) 1578 1643 0.750
Median TBL (mL) 1555 1778 Na
Median HBL (mL) 1397 1682 Na
CBL (mL) 1401 1668 0.140
Mean EBL (mL) 104.2 120.6 0.618
Anesthesiologists) of the patient, and/or clinical symptoms
consistent with an anemic picture.
We used a chi-square test for testing the proportions of
cases receiving blood, and Student’s t-test and chi-square
were used for comparing the continuous and categorical
variables, respectively. For the statistical analysis, version 18
of PASW Statistics (SPSS Inc., an IBM Company Headquar-
ters, Chicago, IL) was used. A P < 0.05 was considered
statistically significant.
3. Results
A total of 81 mildly anemic patients who met our study
criteria had revision knee surgery from January 2007 to May
2010. The records of these 81 patients were reviewed and
no diﬀerences in demographic data between cohorts for age
(64.4 versus 63.7 yrs), gender (75% versus 75%), or BMI
(32.5 versus 35.9 kg/m2) were found. The following patient
blood values were similar: preoperative PT (11.0 versus
10.5), preoperative PTT (32.7 versus 29.2), preoperative INR
(1.06 versus 1.056), and preoperative platelet count (237,360
versus 263,070 per mm3) (P > 0.05) (Table 1).
The distribution of patients between cohorts revealed no
diﬀerence in ASA score (P = 1.00). The median postopera-
tive total blood loss was 1778mL for controls and 1555mL
for cases. The median hidden blood loss was 1682mL for
controls and 1397mL for cases. There was no diﬀerence in
average total blood loss between groups (1737 versus 1670)
(P = 0.725). There was no diﬀerence in average hidden blood
loss (1643 versus 1578) (P = 0.7459). The calculated blood
loss (CBL) between cohorts was not diﬀerent (1401mL
versus 1668mL (P = 0.140)) (Table 2) [13, 14].
At admission, the mean hemoglobin level was higher in
the epoetin-α group (13.8 g/dL versus 12.2 g/dL) (P =
0.001); the discharge hemoglobin level was higher in the epo-
etin-α group (10.6 g/dL versus 9.69 g/dL) (P < 0.001). There
was no diﬀerence in mean duration of surgery between
cohorts (epoetin-α versus control: 85.4 minutes versus 92.66
minutes) (P = 0.276) (Table 2). One of the patients in the
control group developed cellulitis four days after surgery
which was completely resolved with antibiotic treatment.
Another control patient developed a pulmonary embolus
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Table 3: Component revisions.
Characteristic Epoetin-α Controls
Component Revisions Number (%) Number (%)
Tibia and femur 23 (82.1%) 43 (84.3%)
23 transfused
Femur 1 (3.6%) 1 (1.75%)
1 transfused
Tibia 1 (3.6%) 2 (3.5%)
1 transfused
Patella 1 (3.6%) 3 (5.3%)
1 transfused
Polyethylene exchange 2 (7.1%) 4 (7.01%)
2 transfused
three days after the indexed operation that was treated
with an inferior vena cava filter. A patient developed a
hemarthrosis five days post-op and another patient devel-
oped a mechanical failure. One patient in the epoetin-α
group (65-year-old male) passed away seven months after
the index procedure due to cardiac arrest. An additional
patient developed an uncomplicated acute postoperative
deep venous thrombosis. No other minor or major compli-
cation, either local or systemic, was recorded.
In the epoetin-α group, 0% of the patients (0 of 28)
required blood transfusion. This was significantly lower than
the control group where 53% of the patients (28 of 53)
received at least one unit of blood transfusion (P = 0.0001).
The purpose of epoetin-α use preoperatively is to optimize
the level of hemoglobin prior to surgery; for our patients who
received an initial complete blood count at our institution
(n = 14 of 28), the hemoglobin increased from 11.97 g/dL to
13.8 g/dL preoperatively (P = 0.001). The average quantities
of epoetin-α doses received were 2.86. The epoetin-α cohort
had a shorter hospital stay (3 versus 3.67, P = 0.042)
(Table 2).
The index revision surgery was defined as any procedure
in which at least tibial, patellar, femoral, or polyethylene
components were exchanged. In the epoetin-α cohort, 23
(82.1%) patients had a tibia and femur revision; the remain-
ing 5 (17.9%) received a single-component revision, 2
(7.10%) were polyethylene exchanges and 1 was for a patella
(3.60%), femur (3.60%), and tibia (3.60%), respectively. In
the control cohort, 43 (84.3%) patients had a tibia and
femur revision; the remaining 10 (17.5%) received a single-
component revision, 4 (7.01%) were polyethylene exchanges,
3 (5.30%) were patella, 2 (3.51%) tibial, and 1 (1.75%)
femoral (Table 3).
4. Discussion
While preoperative hemoglobin levels are a known risk factor
for peri- and postoperative transfusion needs in knee arthro-
plasty [15–17], this is the first study to assess the eﬀect of pre-
operative epoetin-α use on the mildly anemic revision knee
patient. We report that our patients did not require trans-
fusion, had higher postoperative and discharge hemoglobin
levels, and had a shorter length of stay. Epoetin-α success-
fully increased the preoperative hemoglobin levels (from
11.97 g/dL to 13.93 g/dL, resp.). One patient had a deep
venous thrombosis (3.6%), postoperatively.
While epoetin-α may be costly, its use in selected patient
groups may actually reduce total cost (direct and indirect)
during knee arthroplasty [18, 19]; however, Moonen et al.
[9] reported that epoetin-α injection, supplemented by fer-
rofumerate tablets, increased the direct cost per patient
when compared with a retransfusion system. They did note
that without the collection of indirect costs a true cost-
eﬀectiveness analysis could not be performed. Although the
retrospective nature of our study prevented a worthwhile
cost analysis, our experience working with epoetin-α in the
mildly anemic patient has been safe and eﬃcacious, and we
hypothesize that the elevated postoperative hemoglobin level
may increase the patient’s short-term outcome [20]. A Future
randomized study should include direct and indirect cost
data as part of their analysis.
Cushner et al. conducted a retrospective review of 100
consecutive patients who had a revision TKA. Some of the
patient’s received either a closed suction or reinfusion type
drain. Fifty-two percent of the patients were female, which
was lower than the 75% in our cohort. Fifty-eight percent
of their patients participated in the preoperative autologous
donation program (at least one unit of blood), and a signif-
icant decrease in preoperative Hgb levels was found. They
noted that the preoperative autologous donation resulted
in an “orthopaedic-induced anemia.” They also concluded
that autologous donation may not be appropriate because
it predisposed patients to transfusion. All control patients
included in our study had mild anemia (10–13 g/dL) prior
to surgery (whether preoperative autologous donation was
utilized or not). Greater than half of our control patient’s
were transfused (17% allogeneic) with an average of 256cc’s
of blood.
De Andrade et al. compared epoetin-α to a placebo in a
primary knee arthroplasty double-blind study. They found
that those with a mild anemia (10–13 g/dL) who received
epoetin-α (300 IU/kg or 100 IU/kg) had a lower allogeneic
transfusion rate relative to placebo [21]. Additionally, Stowell
et al. found that epoetin-α weekly doses of 40,000 units
raised hemoglobin levels from 12.3 g/dL to 13.8 g/dL, preop-
eratively. Their patients maintained higher levels peri- and
postoperatively compared to a cohort who had preoperative
autologous donation [22]. Our revision patients responded
with an increased hemoglobin level from pre- to postop
of 11.97 g/dL to 13.93 g/dL, respectively. We believe this
change was clinically significant and most likely prevented
peri- or postoperative transfusions, decreased length of stay,
and allowed patients to more actively participate in physical
therapy sooner [20, 21].
According to Sehat et al., there may be hidden blood
loss into the soft tissue and joint of an arthroplasty patient
[14]. In addition, two studies using radiolabeled RBC’s
showed unexplained peri-operative blood loss likely into
tissue compartments [23, 24]. Our study was not powered to
detect such a diﬀerence in hidden and total blood loss
between patient groups; however, our average total and
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hidden blood losses were elevated when compared to the
primary knee patient [14]. In addition, when we attempted
to evaluate total and hidden losses, we noted a few important
imperfections. For example, the estimated blood loss (EBL)
is a nonstandardized subjective measure that likely varies
as much inter- as intrainstitutionally. Moreover, the median
value has often been used to report hidden and total blood
loss findings because the range of losses had tremendous
variability [13]. However, an interesting finding derived from
such calculations is that a total knee arthroplasty, on average,
has a higher hidden blood loss than total hip arthroplasty
[14]. The change in hemoglobin from pre- to postop in our
study cohort was 3.24 g/dL. Such a change was similar to
those recorded by Sehat et al. who noted that a TKA without
reinfusion had a change of 3.3 g/dL and 2.8 g/dL after re-
infusion [14].
Our study resulted in not only an increase in preoperative
hemoglobin levels, but also a higher hemoglobin level at
time of discharge. This is substantial considering the control
patients discharge counts included blood transfused.
We performed all cases under tourniquet control, which
is thought to cause fibrinolysis [25, 26]. Furthermore, post-
operative fibrinolysis is also thought to occur transiently
[27]. This increased activity may elevate blood loss after revi-
sion total knee arthroplasty [28, 29]. Interestingly, epoetin-
α has been found to transiently increase the number of
circulating platelets as well as improve their function. This
may potentially decrease total blood loss for the revision
knee patient [30]. There is also an antiapoptotic activity
that in preclinical and small clinical studies has been shown
to protect cells from hypoxic and ischemic events [31–33].
However, cancer and chronic renal failure trial patients had
an increased risk of thrombotic complications and death
[34–36]. Our study population developed one uncompli-
cated deep venous thrombosis (3.6%). However, one control
patient developed a pulmonary embolism (2.3%). The
control patient was a 93 yo female with an ASA score of 3 and
BMI of 31, while the study patient was a 63 yo male with an
ASA score of 4 and BMI of 31; neither patient had a history of
deep venous thrombosis or pulmonary embolus in their past.
All patients received the same postoperative treatment course
that consisted of antithromboprophylaxis, early ambulation,
and physical therapy. Additionally, no study patient had an
ischemic event.
No study is without limitation. First, we collected all data
retrospectively and there are inherent limitations in such
study design. Therefore, we attempted to reduce potential
confounding by patient-matching based on age, gender,
BMI, and American Society of Anesthesiology (ASA) scores.
We also included a consecutive series of case patients. Sec-
ond, spinal anesthesia is known to be associated with less
perioperative blood loss in TKA when compared to general
anesthesia [37]. The majority of our patients underwent
spinal anesthesia but a few patients required general anes-
thesia. Third, the percentage of patients who received pre-op
iron, folic acid, vitamin B12, and multivitamins was elevated
in the study group which may have enhanced the eﬀects of
our epoetin-α dosing regimen. Fourth, our patient selection
was limited to those without a thromboembolic history.
Fifth, the triggers for transfusion are physician dependent.
To better control for this, we only included cases performed
by two surgeons who utilize similar transfusion protocols.
Furthermore, those patients treated with epoetin-α did not
require any transfusions. Therefore it is unlikely that a true
clinical diﬀerence in transfusion criteria occurred between
our cohorts.
In conclusion, the present study may suggest that epo-
etin-α has a role in reducing the need for blood transfusion
in the mildly anemic patient who undergoes revision knee
surgery. It may also decrease patient length of stay allowing
for earlier readiness to resume normal activities or meet
short-term milestones [20]. Its use may also be an attractive
alternative to autologous donation. A randomized study to
evaluate the direct and indirect costs of such a treatment
methodology in the mildly anemic revision patient may be
warranted.
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